Nucleic acid molecule with Anti-inflammatory, Anti-coagulant and organ-protective properties

一种核酸分子、器官保护的技术,应用在具有抗炎及抗凝血和器官保护性能的核酸分子领域

CN111386121APending Publication Date: 2020-07-07APATAM CORP
17 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2020-07-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a nucleic acid molecule or a composition comprising said molecule for use as an anti-inflammatory and / or anti-coagulant and / or organ-protective medicament. The invention alsorelates to a use of said nucleic acid molecule or said composition, for the manufacture of a medicament for preventing, treating, regressing, curing and / or delaying a disease or a condition wherein inflammation and / or coagulation and / or organ damage or failure occurs in an individual. Finally, the invention further relates to a method for alleviating one or more symptom(s) and / or characteristic(s)and / or for improving a parameter of a disease or condition wherein inflammation and / or coagulation and / or organ damage or failure occur in an individual, the method comprising administering to said individual said nucleic acid molecule or said composition.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to nucleic acid molecules or compositions comprising said molecules which are suitable as anti-inflammatory and / or anticoagulant and / or organ protective agents. The invention also relates to said nucleic acid molecule or said composition for use in the manufacture of a disease or condition for the prevention, treatment, regression, cure and / or delay of inflammation or / and coagulation and / or organ damage or failure in an individual use of the drug. Finally, the present invention further relates to methods for alleviating one or more symptoms and / or characteristics and / or improving parameters of a disease or condition in which inflammation and / or coagulation and / or organ damage or failure occurs in an individual, the The method comprises administering said nucleic acid molecule or said composition to the individual. Background technique

[0002] Disseminated intravascular coagulation (DIC) is characterized by systemic acti...

Examples

Embodiment 1

[0209] Example 1: Anticoagulant activity of SEQ ID NO:2

[0210] tailbleed model

[0211] Materials and methods

[0212] the rat

[0213] A total of 36 Sprague-Dawley male and female rats were used and divided into 6 groups, each consisting of 6 animals. Animal handling was performed according to the guidelines of the National Institute of Health and the Association for Assessment and Accreditation of Laboratory Animal Care. Animals had free access to a commercially available rodent diet (Teklad certified global 18% protein diet catalog number: 2018SC). Animals had free access to autoclaved and acidified drinking water (pH 2.5-3.5) obtained from a municipal supply. Animals were housed under standard laboratory conditions, the air was conditioned and filtered with an adequate fresh air source. Animals were maintained in a climate-controlled environment.

[0214] Compounds and Preparations

[0215] SEQ ID NO: 2 (Biospring) (100 mg) was dissolved in 5 mL of saline to f...

Embodiment 2

[0227] Example 2: Anticoagulant activity of SEQ ID NO:2.

[0228] arteriovenous shunt model

[0229] Materials and methods

[0230] the rat

[0231] This study was performed at Shanghai WuXi AppTec Co., Ltd. and according to WuXi IACUC standard animal procedures and compliance with the Animal Welfare Act (Animal Welfare Act), the care and use of laboratory animals (Guide for the Care and Use of Laboratory Animals) IACUC Guidelines and Office of Laboratory Animal Welfare (OLAW). Male Sprague-Dawley rats (Vital River; Beijing, PR China) weighing in the range of 150-200 g were fed a rodent diet ad libitum. Animals had free access to autoclaved and acidified drinking water. Animals are housed under standard laboratory conditions, with air conditioning and filtration of an adequate fresh air source. Animals were housed in a climate-controlled environment.

[0232] compound

[0233] Rivaroxaban (10 mg / kg) was dissolved in water and stored at 4°C. 20 mg of SEQ ID NO:2 (Bi...

Embodiment 3

[0249] Example 3: Anticoagulant activity of SEQ ID NO:2 in ferric chloride-induced arterial thrombosis model

[0250] Materials and methods

[0251] the rat

[0252] Animal handling was performed according to National Institute of Health (NIH) and Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines. A total of 36 Sprague-Dawley rats (Envigo RMS) were divided into 6 groups, each group comprising 6 animals (3 males and 3 females). At the beginning of the study, Sprague-Dawley male rats had an average body weight of 350 g. Female rats have a body weight of 243 g. Both were fed a rodent diet ad libitum. Animals had free access to autoclaved and acidified drinking water. Animals were housed under standard laboratory conditions, the air was conditioned and filtered with an adequate fresh air source. Animals were maintained in a climate-controlled environment.

[0253] Compounds and Preparations

[0254] SEQ ID NO: 2 (Biospring) (100 m...